Eli Lilly is a major pharmaceutical corporation which develops, manufactures and markets pharmaceutical products. The company has major R&D facilities in seven countries and manufacturing facilities in 13 countries.
Eli Lilly will focus on its ‘innovation-driven’ strategy and invest in R&D with the goal of delivering a steady flow of innovative products. The company will also build the capabilities to manufacture these products and market them effectively around the world, and augment its own capabilities and resources through partnerships.
Eli Lilly is readying a generation of molecules for the market and restocking its early-stage pipeline. Its strength in developing both small-molecule and large-molecule ‘biotech’ medicines is said to distinguish Eli Lilly from most other major pharmaceutical companies.
Headquartered in Indianapolis, Indiana, US, Eli Lilly has approximately 40,360 employees worldwide and net sales in 2009 of $22bn.
Download the The ICIS Top 100 Chemical Companies listing here
Chairman: John Lechleiter
Member: Michael Cook
Member: Michael Eskew
Member: Martin Feldstein
Member: George Fisher
Member: Erik Fyrwald
Member: Alfred Gilman
Member: Karen Horn
Member: Ellen Marram
Member: Franklyn Prendergast
Member: Kathi Seifert
Eli Lilly & Company Lilly Corporate Centre PO Box 88665 Indianapolis, Indiana 46285US Tel: +1 317 276 2000 Fax: +1 317 277 6139
Eli Lilly is a major pharmaceutical corporation which develops pharmaceutical products. The company has major R&D facilities in seven countries. Its R&D facilities are located in Australia, Belgium, Canada, England, Germany, Japan, Singapore, Spain, and the US. It conducts clinical research in more than 60 countries around the world. Manufacturing facilities are located in Brazil, China, Egypt, England, France, Germany, Ireland, Italy, Japan, Korea, Mexico, Pakistan, Puerto Rico, Spain and the US. In addition Eli Lilly operates 14 administrative, manufacturing and R&D plants in the US and Puerto Rico.
More about Eli Lilly Structure
Eli Lilly will focus on its ‘innovation-driven’ strategy. The company has built what it states as being ‘one of the most productive R&D organisations in the pharmaceutical industry’. It is currently readying a generation of molecules for the market and restocking its early-stage pipeline. It states that ‘unlike most of its peers’, it does not have any major patent expirations coming up in the next several years. Its strength in developing both small-molecule and large-molecule ‘biotech’ medicines is said to also distinguish Eli Lilly from most other major pharmaceutical companies. (Edited from 'Letter to shareholders' - annual report). ICIS also provides you with key financial data listed in table form.
More about Eli Lilly Strategy & Financial Highlights
Get news on Eli Lilly plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Find details on other chemical companies and suppliers with
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database
INSIGHT: China may see major ethylene shortfall by 2019
"At $50-90/bbl for Brent, UBS estimates the internal rate of return (IRR) for China CTO/MTO projects range from 5-10% – mostly too low to justify inve
VIDEO: ICIS Special Report: Innovation is key to success